Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.

MLA

Okura, Yasushi, et al. “Combined Treatment with Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) and Angiotensin-II Type 1 Receptor Blocker (Losartan) Suppresses Progression in a Non-Diabetic Rat Model of Steatohepatitis.” Hepatology Research, vol. 47, no. 12, Nov. 2017, pp. 1317–28. EBSCOhost, https://doi.org/10.1111/hepr.12860.

APA

Okura, Y., Namisaki, T., Moriya, K., Kitade, M., Takeda, K., Kaji, K., Noguchi, R., Nishimura, N., Seki, K., Kawaratani, H., Takaya, H., Sato, S., Sawada, Y., Shimozato, N., Furukawa, M., Nakanishi, K., Saikawa, S., Kubo, T., Asada, K., & Yoshiji, H. (2017). Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. Hepatology Research, 47(12), 1317–1328. https://doi.org/10.1111/hepr.12860

Chicago

Okura, Yasushi, Tadashi Namisaki, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Kosuke Kaji, Ryuichi Noguchi, et al. 2017. “Combined Treatment with Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) and Angiotensin-II Type 1 Receptor Blocker (Losartan) Suppresses Progression in a Non-Diabetic Rat Model of Steatohepatitis.” Hepatology Research 47 (12): 1317–28. doi:10.1111/hepr.12860.